Jason P. Rhodes, Director at Dyne Therapeutics, Inc. (DYN), sold 93,068 shares at $30.05 ($2.8M) on 2024-03-01, disclosed to the SEC on 2024-03-05.
Scheduled sale ($2.8M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $30.05 | 17,099 | $514K | 18.4% |
| 2 | $30.05 | 17,099 | $514K | 18.4% |
| 3 | $30.05 | 29,435 | $885K | 31.6% |
| 4 | $30.05 | 29,435 | $885K | 31.6% |
| Total | $30.05 avg | 93,068 | $2.8M | 100% |
| Filing → |
| DYN | SELL | 2026-06-30 | $10.7M | — | Filing → |
| DYN | SELL | 2026-06-26 | $5.6M | — | Filing → |
| DYN | SELL | 2026-05-06 | $1.9M | — | Filing → |